Prospective Data Mining of Six Products in the US FDA Adverse Event Reporting System: Disposition of Events Identified and Impact on Product Safety Profiles

Drug Safety

Volumn 33, Issue 2, 2010, Pages 139-146

  Bailey, Steven ^a   Singh, Ajay ^a   Azadian, Robert ^a   Huber, Peter ^a   Blum, Michael ^a  

^a Wyeth   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

ARTICLE; DRUG INDICATION; DRUG INFORMATION; DRUG LABELING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HUMAN; PRIORITY JOURNAL; UNITED STATES; UNSPECIFIED SIDE EFFECT;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DATA MINING; DATABASES, FACTUAL; HUMANS; PHARMACEUTICAL PREPARATIONS; PILOT PROJECTS; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 75649103611     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11319000-000000000-00000     Document Type: Article

References (29)

1. Hauben M, Madigan D, Gerrits CM, et al. The role of datamining in pharmacovigilance. Expert Opin Drug Saf 2005 Sep; 4 (5): 929-948
2. Almenoff JS, Pattishall EN, Gibbs TG, et al. Novel statistical tools for monitoring the safety of marketed drugs. Clin Pharmacol Ther 2007 Aug; 82 (2): 157-166
3. Bate A, Edwards IR. Data mining in spontaneous reports. Basic Clin Pharmacol Toxicol 2006 Mar; 98 (3): 324-330
4. Stephenson WP, Hauben M. Datamining for signals in spontaneous reporting databases: proceed with caution. Pharmacoepidemiol Drug Saf 2007; 16: 359-365
5. Hauben M. Early postmarketing drug safety surveillance: data mining points to consider. Ann Pharmacother 2004 Oct; 38 (10): 1625-1630
6. Hauben M, Horn S, Reich L. Potential use of data-mining algorithms for the detection of 'surprise' adverse drug reactions. Drug Saf 2007; 30 (2): 143-155
7. Roux E, Thiessard F, Fourrier A, et al. Evaluation of statistical association measures for the automatic signal generation in pharmacovigilance. IEEE Trans Inf Technol Biomed 2005 Dec; 9 (4): 518-527
8. Matsushita Y, Kuroda Y, Niwa S, et al. Criteria revision and performance comparison of three methods of signal detection applied to the spontaneous reporting database of a pharmaceutical manufacturer. Drug Saf 2007; 30 (8): 715-726
9. Almenoff JS, LaCroix KK, Yuen NA, et al. Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department. Drug Saf 2006; 29 (10): 875-887
10. Kubota K, Koide D, Hirai T. Comparison of data mining methodologies using Japanese spontaneous reports. Phar-macoepidemiol Drug Saf 2004 Jun; 13 (6): 387-394
11. Gould AL. Practical pharmacovigilance analysis strategies. Pharmacoepidemiol Drug Saf 2003 Oct-Nov; 12 (7): 559-574
12. van Puijenbroek EP, Bate A, Leufkens HG, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 2002 Jan-Feb; 11 (1): 3-10
13. Lindquist M, Stahl M, Bate A, et al. A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database. Drug Saf 2000 Dec; 23 (6): 533-542
14. Lehman HP, Chen J, Gould AL, et al. An evaluation of computer-aided disproportionality analysis for post-marketing signal detection. Clin Pharmacol Ther 2007 Aug; 82 (2): 173-180
15. van Puijenbroek EP, van Grootheest K, Diemont WL, et al. Determinants of signal selection in a spontaneous reporting system for adverse drug reactions. Br J Clin Pharmacol 2001 Nov; 52 (5): 579-586
16. Hauben M, Reich L. Potential utility of data-mining algorithms for early detection of potentially fatal/disabling adverse drug reactions: a retrospective evaluation. J Clin Pharmacol 2005 Apr; 45: 378-384
17. DuMouchel W, Smith E, Beasley R, et al. Association of asthma therapy and churg-strauss syndrome: an analysis of postmarketing surveillance data. Clin Ther 2004; 26 (7): 1092-1104
18. Almenoff J, Tonning JM, Gould AL, et al. Perspective on the use of datamining in pharmacovigilance. Drug Saf 2005; 28 (11): 981-1007
19. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001 Oct-Nov; 10 (6): 483-486
20. Bate A, Lindquist M, Edwards IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 1998 Jun; 54 (4): 315-321
21. Noren GN, Bate A, Orre R, et al. Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events. Stat Med 2006 Nov 15; 25 (21): 3740-3757
22. DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am Stat 1999; 53 (3): 177-190
23. Hauben M. A brief primer on automated signal detection. Ann Pharmacother 2003 Jul-Aug; 37 (7-8): 1117-1123
24. Hauben M, Zhou X. Quantitative methods in pharmaco-vigilance: focus on signal detection. Drug Saf 2003; 26 (3): 159-186
25. Szarfman A, Machado S, O'Neill R. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the us FDA's spontaneous reports database. Drug Saf 2002; 25 (6): 381-392
26. Hauben M, Reich L, Chung S. Postmarketing surveillance of potentially fatal reactions to oncology drugs: potential utility of two signal-detection algorithms. Eur J Clin Pharmacol 2004; 60: 747-750
27. Hauben M, Reich L, Gerrits CM, et al. Illusions of objectivity and a recommendation for reporting data mining results. Eur J Clin Pharmacol 2007 May; 63 (5): 517-521
28. Hauben M, Reich L. Safety related drug-labelling changes: findings from two data mining algorithms. Drug Saf 2004; 27 (10): 735-744
29. Hochberg AM, Reisinger SJ, Pearson RK, et al. Using data mining to predict safety actions from FDA adverse event reporting system data. Drug Info J 2007; 41 (5): 633-643